RHABDOMYOSARCOMA

This study is testing a personalized peptide vaccine for children and young adults (up to age 30) with metastatic fusion-driven sarcomas (Ewing sarcoma, rhabdomyosarcoma, synovial sarcoma) who have completed standard treatment. The vaccine is custom-made for each patient based on…

This early-phase study tests whether giving specially engineered immune cells (HER2-CAR T cells) together with an immune checkpoint inhibitor (pembrolizumab or nivolumab) is safe and can help people with advanced sarcoma. About 25 participants will receive chemotherapy to prepare…

This study is for children, teens, and young adults up to age 39 with sarcoma that has spread to a few other places in the body. Researchers want to see if giving extra radiation to those spread spots, along with usual treatment, can help patients live longer without the cancer g…

This early-phase study tests a new type of immunotherapy for adults with solid tumors that have a specific marker called GPC3. The treatment involves taking a patient's own T cells, adding genes to help them recognize and attack cancer cells, and then giving them back. The study …

This early-stage trial tests a treatment where a child's own immune cells are collected, modified to better attack cancer, and given back as a one-time infusion. It is for children and young adults up to age 21 with solid tumors that have come back or not responded to standard th…

This early-phase study tests a combination of two types of immune cells (B7-H3 CAR T cells and PRAME-specific T cells) in children with relapsed or treatment-resistant cancers like rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, and Wilms tumor. The main goal is to check safety a…

This study tests a stem cell transplant that removes certain immune cells (alpha/beta T cells and CD19+ B cells) and adds a drug called zoledronic acid. The goal is to help the donor cells attack the tumor without causing severe side effects. It is for children and young adults a…

This study tests a new drug called Becotatug Vedotin in children aged 2 to 18 with certain cancers (like head and neck, brain, or kidney tumors) that have come back or spread. The drug targets a protein called EGFR found on many cancer cells. The main goal is to see if the drug i…

This early-phase study tests a four-drug combination (vorinostat, vincristine, irinotecan, and temozolomide) in children, teens, and young adults up to age 30 whose solid tumors or brain cancers have returned or not responded to standard treatment. The main goals are to find a sa…

This study tests a radioactive drug (lutetium Lu 177 edotreotide) in children aged 2 to 17 with cancers that have a specific marker (SSTR-positive). The goal is to find the best dose and see if it is safe. About 20 children whose cancer has not responded to prior treatment will t…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help children whose solid tumors have come back or not responded to previous treatment. About 23 children with relapsed/refractory solid tumors, including rhabdomyosarcoma, will recei…

This early-phase trial tests a new treatment for children and young adults (ages 3–39) with rhabdomyosarcoma that has returned or not responded to standard therapy. The treatment uses the patient's own immune cells, modified in a lab to better recognize and attack cancer cells. T…

This early-stage trial tests a new type of immunotherapy for children and young adults with certain solid tumors that have come back or not responded to treatment. The therapy uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer c…

This early-phase trial tests a new experimental treatment called CARE T cells for children and young adults with certain solid tumors (like liver cancer or Wilms tumor) that have returned or not responded to standard therapy. The treatment involves taking a patient's own immune c…

This study tests a new drug called PEEL-224 combined with two standard chemotherapy drugs (vincristine and temozolomide) in adolescents and young adults whose sarcomas have come back or not responded to treatment. The goal is to find the safest dose and see if the combination shr…

This study tests an experimental pill called silmitasertib combined with standard chemotherapy in children and young adults (under 30) whose solid tumors (like neuroblastoma, Ewing sarcoma, or osteosarcoma) have come back or not responded to treatment. The goal is to find a safe …

This early-stage study tests a new type of stem cell transplant for children whose blood cancers or solid tumors have come back or are hard to treat. Doctors use a special method to remove certain immune cells from the donor's stem cells and give a drug called zoledronate after t…

This research study aims to discover new genes that may cause cancer to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had childhood cancers. Participants will not receive direct treatment o…

This study looks at whether a safe green dye, called ICG, can help surgeons see if cancer has spread to nearby lymph nodes in children with solid tumors. About 10 children under 18 who need lymph node surgery will get the dye injected during their operation. The goal is to see if…